DUBLIN–(BUSINESS WIRE)–The “Insomnia – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Insomnia – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 9, 7, 6, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Insomnia – Overview
Insomnia – Therapeutics Development
Insomnia – Therapeutics Assessment
Insomnia – Companies Involved in Therapeutics Development
Insomnia – Drug Profiles
Insomnia – Dormant Projects
Insomnia – Discontinued Products
Insomnia – Product Development Milestones
- Amherst Pharmaceuticals LLC
- Artelo Biosciences Inc
- Biohemp International Inc
- Cannabis Science Inc
- Cennerv Pharma (S) Pte Ltd
- Ci Therapeutics
- Eisai Co Ltd
- EUSOL Biotech Co Ltd
- Evotec SE
- Grupo Ferrer Internacional SA
- Guangdong East Sunshine Pharmaceutical Co Ltd
- Idorsia Pharmaceutical Ltd
- Imbrium Therapeutics LP
- Intra-Cellular Therapies Inc
- Johnson & Johnson
- Linnet BioPharmaceuticals Inc
- M et P Pharma AG
- NB Health Laboratory Co Ltd
- Neurim Pharmaceuticals Ltd
- NeuroFix Therapeutics LLC
- Overseas Pharmaceuticals Ltd
- Renascence Therapeutics Ltd
- Reviva Pharmaceuticals Inc
- Sage Therapeutics Inc
- Taisho Pharmaceutical Holdings Co Ltd
- Tetranov International Inc
- Tritech Biopharmaceuticals Co Ltd
- Yangtze River Pharmaceutical Group
- Zelira Therapeutics Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jmjzst